loader image
Saturday, March 29, 2025
74.2 F
McAllen
We Welcome your Press Release
- Advertisement -

Post-Exposure Prophylactic Use of Monoclonal Antibodies

Translate to Spanish or other 102 languages!

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.
The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. Image for illustration purposes.

Mega Doctor News

- Advertisement -

Edinburg, TX – Monoclonal antibody infusion has been used quite extensively in treating mild-moderated SARS-CoV-2 infection. The primary objective of this treatment is to prevent the progression of disease to a severe stage requiring hospitalization. At DHR Health and DHR Health Institute for Research & Development, we have infused REGEN-COV monoclonal antibody to over 500 patients with mild-moderate SARS-CoV-2 infection with very satisfactory outcome. This included adults, children and pregnant women who were at high risk for developing severe COVID-19 disease.

“We are embarking on a new project that is both FDA and IRB-approved to infuse monoclonal antibodies to asymptomatic high-risk individuals who are COVID-19 negative but have been exposed to a COVID-19 positive patient” said Sohail Rao, MD, MA, DPhil, President & CEO, DHR Health Institute for Research & Development. “The purpose of this initiative is to prevent the development of SARS-CoV-2 infection in qualified adults and children 12 years of age or over who are exposed to a COVID-19 positive patient for at least 15 minutes in a 24-hour period”.

The study entails a single treatment with REGEN-COV monoclonal antibody which is either infused intravenously or administered subcutaneously. To learn more about who would qualify for this treatment, please visit this website:https://dhrresearch.org/wp-content/uploads/2021/08/CHECKLIST-08-08-2021-1.pdf  or call the post-exposure prophylaxis hotline (956) 362-2357 (9:00 a.m. – 5:00 p.m.; M-F) for more information.

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

STHS Behavioral: Occupational Therapy’s Role in Mental Health Treatment, April 3rd

Mega Doctor News Occupational therapy plays a vital role in mental health...

DHR Health Welcomes Dr. Andres Saenz, Neurologist

Mega Doctor News EDINBURG, Texas - DHR Health, one of the largest physician-owned...

STHS Kicking Off National Donate Life Month with a Candlelight Vigil, April 2nd

Mega Doctor News In the United States, there are currently 104,619 men,...

DHR Health Statement on Cyber Event and Ongoing Patient Care

Mega Doctor News DHR Health continues to respond to a cyber event that occurred on March 20, 2025. As this is an active investigation, we are limited...
- Advertisement -
×